Please use this identifier to cite or link to this item:
Title: Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.
Authors: Errarte, Peio
Beitia, Maider
Perez, Itxaro
Manterola, Lorea
Lawrie, Charles H
Solano-Iturri, Jon Danel
Calvete-Candenas, Julio
Unda, Miguel
López, José I
Larrinaga, Gorka
metadata.dc.subject.mesh: Adult
Aged, 80 and over
Angiotensin-Converting Enzyme 2
Carcinoma, Renal Cell
Glutamyl Aminopeptidase
Kaplan-Meier Estimate
Middle Aged
Multivariate Analysis
Peptidyl-Dipeptidase A
Proportional Hazards Models
Tissue Array Analysis
Issue Date: 15-Aug-2017
Abstract: The discovery of the intrarenal renin-angiotensin system (iRAS), which regulates angiogenesis, cell differentiation and proliferation, has opened new perspectives in the knowledge of kidney carcinogenesis. In this study we analyzed the immunohistochemical expression and fluorimetric activity of four key peptidases of iRAS in tumor tissue (n = 144) and serum samples (n = 128) from patients with renal neoplasms. Neutral endopeptidase (NEP/CD10), Angiotensin-converting enzyme-2 (ACE2), and aminopeptidase A (APA) were expressed in tumor cells whilst Angiotensin-converting enzyme (ACE) was expressed in the endothelial cells of intratumor blood vessels. The expression of ACE, ACE2 and NEP/CD10 was highest in clear cell renal cell carcinoma (CCRCC) and papillary renal cell carcinoma (PRCC). The expression of these enzymes correlated with CCRCC aggressiveness. In addition, NEP/CD10 correlated with 15-year overall survival. On the other hand, APA expression was decreased in CCRCC with higher grade and stage. The loss of expression of APA independently correlated with a worse 15-year overall survival. Serum activity of ACE2, NEP/CD10 and APA was significantly higher in renal tumor patients than in healthy subjects. Serum ACE activity was lower in high grade and metastatic CCRCC patients, and NEP/CD10 activity was negatively correlated with UISS (UCLA Integrated Staging System) and SSIGN (Mayo Clinic stage, size, grade and necrosis model) scores and with overall survival of CCRCC patients. These results suggest a metabolic imbalance of iRAS in renal tumors. This finding should be taken into account in the search of new diagnostic, prognostic and therapeutic tools for this disease.
metadata.dc.identifier.doi: 10.1371/journal.pone.0181711
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC5557356.pdf8,17 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons